CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: From The Danish “MALOVA” Ovarian Cancer Study
- 31 March 2007
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 104 (3), 508-515
- https://doi.org/10.1016/j.ygyno.2006.09.028
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countriesActa Obstetricia et Gynecologica Scandinavica, 2005
- Biomarkers of ovarian tumoursEuropean Journal Of Cancer, 2004
- Tissue microarrays: a practical guidePathology, 2004
- Immunotherapy of ovarian cancer with antibodies: a focus on oregovomabExpert Opinion on Biological Therapy, 2004
- Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition AnalysisClinical Cancer Research, 2004
- Immunohistochemistry in gynaecological pathology: a reviewPathology, 2004
- Tissue microarrays (TMAs) for high-throughput molecular pathology researchInternational Journal of Cancer, 2001
- How Cancer ArisesScientific American, 1996
- Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA 125 antigen and c‐erbB‐2 oncogeneActa Obstetricia et Gynecologica Scandinavica, 1995
- The Role of Serum Tetranectin, CA 125, and a Combined Index as Tumor Markers in Women with Pelvic TumorsGynecologic Oncology, 1995